Form 4: Pulse Biosciences CEO Increases Stake via ATM Offering

Pulse Biosciences CEO Paul A. Laviolette acquired 15,000 shares of common stock through the company's at-the-market offering program.

Summary

• CEO Paul A. Laviolette purchased 15,000 shares of Pulse Biosciences (PLSE) common stock.
• The transaction occurred on May 11, 2026, at a price of $19.69 per share.
• The acquisition was executed through the company's existing at-the-market (ATM) equity offering program.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive signal because the CEO is using personal capital to increase their equity stake in the company.

Positives

• Insider confidence is demonstrated by the CEO's direct purchase of company stock.
• The purchase was made at market price, signaling alignment with shareholder interests.

Negatives

• None identified in this filing.

Risks

• Reliance on ATM equity offering programs can lead to shareholder dilution if utilized frequently.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an insider transaction.

Management Comments

• The shares were acquired in a negotiated transaction through the Company's at-the-market equity offering program at the prevailing market bid price or better.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a CEO, is generally viewed as a positive signal of management's belief in the company's long-term valuation and strategic direction.

Comparison to Industry Standards

• Insider purchases are standard practice for executives looking to demonstrate 'skin in the game' to investors.
• Utilizing an ATM program for insider acquisition is a transparent method of increasing ownership without impacting market liquidity negatively.

Stakeholder Impact

• Shareholders may view this as a vote of confidence in the company's current trajectory.

Next Steps

• Continued monitoring of SEC filings for further insider activity or updates to the ATM program.

Key Dates

Keywords

Pulse Biosciences, PLSE, Insider Trading, CEO, Equity Offering, ATM